Logo image of DUOT

DUOS TECHNOLOGIES GROUP INC (DUOT) Stock Fundamental Analysis

NASDAQ:DUOT - Nasdaq - US2660424076 - Common Stock - Currency: USD

7.3  -0.08 (-1.08%)

After market: 7.24 -0.06 (-0.82%)

Fundamental Rating

1

DUOT gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 284 industry peers in the Software industry. DUOT has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, DUOT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year DUOT has reported negative net income.
In the past year DUOT has reported a negative cash flow from operations.
In the past 5 years DUOT always reported negative net income.
DUOT had a negative operating cash flow in each of the past 5 years.
DUOT Yearly Net Income VS EBIT VS OCF VS FCFDUOT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

DUOT has a worse Return On Assets (-29.61%) than 73.24% of its industry peers.
DUOT's Return On Equity of -195.88% is on the low side compared to the rest of the industry. DUOT is outperformed by 79.23% of its industry peers.
Industry RankSector Rank
ROA -29.61%
ROE -195.88%
ROIC N/A
ROA(3y)-56.91%
ROA(5y)-67.89%
ROE(3y)-284.96%
ROE(5y)-396.89%
ROIC(3y)N/A
ROIC(5y)N/A
DUOT Yearly ROA, ROE, ROICDUOT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K 1.5K

1.3 Margins

DUOT has a worse Gross Margin (15.12%) than 83.80% of its industry peers.
In the last couple of years the Gross Margin of DUOT has declined.
The Profit Margin and Operating Margin are not available for DUOT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 15.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-32.94%
DUOT Yearly Profit, Operating, Gross MarginsDUOT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

0

2. Health

2.1 Basic Checks

DUOT does not have a ROIC to compare to the WACC, probably because it is not profitable.
DUOT has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, DUOT has more shares outstanding
DUOT has a worse debt/assets ratio than last year.
DUOT Yearly Shares OutstandingDUOT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
DUOT Yearly Total Debt VS Total AssetsDUOT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

DUOT has an Altman-Z score of -2.23. This is a bad value and indicates that DUOT is not financially healthy and even has some risk of bankruptcy.
DUOT has a worse Altman-Z score (-2.23) than 76.76% of its industry peers.
A Debt/Equity ratio of 0.34 indicates that DUOT is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.34, DUOT is doing worse than 61.27% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z -2.23
ROIC/WACCN/A
WACC8.78%
DUOT Yearly LT Debt VS Equity VS FCFDUOT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

A Current Ratio of 0.53 indicates that DUOT may have some problems paying its short term obligations.
DUOT has a Current ratio of 0.53. This is amonst the worse of the industry: DUOT underperforms 89.44% of its industry peers.
A Quick Ratio of 0.50 indicates that DUOT may have some problems paying its short term obligations.
With a Quick ratio value of 0.50, DUOT is not doing good in the industry: 89.79% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.53
Quick Ratio 0.5
DUOT Yearly Current Assets VS Current LiabilitesDUOT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

5

3. Growth

3.1 Past

DUOT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.27%, which is quite impressive.
DUOT shows a strong growth in Revenue. In the last year, the Revenue has grown by 89.27%.
Measured over the past years, DUOT shows a very negative growth in Revenue. The Revenue has been decreasing by -11.80% on average per year.
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.63%
Revenue 1Y (TTM)89.27%
Revenue growth 3Y-4.12%
Revenue growth 5Y-11.8%
Sales Q2Q%362.51%

3.2 Future

Based on estimates for the next years, DUOT will show a very strong growth in Earnings Per Share. The EPS will grow by 45.73% on average per year.
Based on estimates for the next years, DUOT will show a very strong growth in Revenue. The Revenue will grow by 117.51% on average per year.
EPS Next Y72.68%
EPS Next 2Y45.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year228.83%
Revenue Next 2Y117.51%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DUOT Yearly Revenue VS EstimatesDUOT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
DUOT Yearly EPS VS EstimatesDUOT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -2 -4 -6 -8

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

DUOT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 42.10, which means the current valuation is very expensive for DUOT.
The rest of the industry has a similar Price/Forward Earnings ratio as DUOT.
When comparing the Price/Forward Earnings ratio of DUOT to the average of the S&P500 Index (21.46), we can say DUOT is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 42.1
DUOT Price Earnings VS Forward Price EarningsDUOT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DUOT Per share dataDUOT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

DUOT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
DUOT's earnings are expected to grow with 45.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.73%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

DUOT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DUOS TECHNOLOGIES GROUP INC

NASDAQ:DUOT (6/24/2025, 8:00:00 PM)

After market: 7.24 -0.06 (-0.82%)

7.3

-0.08 (-1.08%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-11 2025-08-11
Inst Owners23.45%
Inst Owner Change11.07%
Ins Owners23.93%
Ins Owner Change0.38%
Market Cap85.05M
Analysts82.5
Price Target12.75 (74.66%)
Short Float %1.49%
Short Ratio1.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.15%
Min EPS beat(2)-36.26%
Max EPS beat(2)1.96%
EPS beat(4)2
Avg EPS beat(4)-8.16%
Min EPS beat(4)-36.26%
Max EPS beat(4)29.41%
EPS beat(8)3
Avg EPS beat(8)-25.98%
EPS beat(12)6
Avg EPS beat(12)-17.78%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-17.5%
Min Revenue beat(2)-47.91%
Max Revenue beat(2)12.9%
Revenue beat(4)3
Avg Revenue beat(4)-0.78%
Min Revenue beat(4)-47.91%
Max Revenue beat(4)18.47%
Revenue beat(8)3
Avg Revenue beat(8)-18.79%
Revenue beat(12)5
Avg Revenue beat(12)-13.45%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.7%
PT rev (3m)16.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.22%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.17%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2%
Revenue NY rev (1m)-0.53%
Revenue NY rev (3m)15.84%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 42.1
P/S 7.62
P/FCF N/A
P/OCF N/A
P/B 16.51
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.2
EYN/A
EPS(NY)0.17
Fwd EY2.38%
FCF(TTM)-0.73
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0.96
BVpS0.44
TBVpS-0.37
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.61%
ROE -195.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 15.12%
FCFM N/A
ROA(3y)-56.91%
ROA(5y)-67.89%
ROE(3y)-284.96%
ROE(5y)-396.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-32.94%
F-Score3
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 84.9%
Cap/Sales 21.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.53
Quick Ratio 0.5
Altman-Z -2.23
F-Score3
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)154.97%
Cap/Depr(5y)158.63%
Cap/Sales(3y)14.73%
Cap/Sales(5y)10.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.63%
EPS Next Y72.68%
EPS Next 2Y45.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)89.27%
Revenue growth 3Y-4.12%
Revenue growth 5Y-11.8%
Sales Q2Q%362.51%
Revenue Next Year228.83%
Revenue Next 2Y117.51%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year80.7%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.06%
OCF growth 3YN/A
OCF growth 5YN/A